Roche's Antibody Cocktail priced at Rs 59,750 per dose

May 24, 2021 11:01

A Covid patient gets oxygen support in Ajmer

Drug majors Roche India and Cipla on Monday announced launch of Roche's Antibody Cocktail in India priced at Rs 59,750 per dose for the treatment of mild to moderate COVID-19 in patients who are at high risk.

"The first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in India offers treatment for two patients," Cipla and Roche said in a joint statement.

Cipla will distribute the product by leveraging its strong distribution strengths across the country, it added. The price for each patient dose [a combined dose of 1,200 mg (600 mg of Casirivimab and 600 mg of Imdevimab)] will be Rs 59,750 inclusive of all taxes.

The maximum retail price for the multi dose pack (each pack can treat two patients) is Rs 1,19,500 inclusive of all taxes As per the statement, the drug will be available through leading hospitals and COVID treatment centers.

« Back to LIVE

TOP STORIES

Paris Olympics: How India's athletes fared on Day 11

Check out how India's athletes fared on Day 11, Tuesday, August 6, 2024:

Olympics PIX: Hocker pulls off upset; Thomas wins 200m

American Cole Hocker delivered one of the all-time Olympic shocks when he won the 1,500 metres gold

Sweeping changes in bill to amend Waqf law; new name, includes non-Muslims

It provides for a broad-based composition of the Central Waqf Council and the State Waqf Boards and ensures the representation of Muslim women and non-Muslims in such bodies.

In Pictures - India go down fighting to Germany in hockey semis

Top-ranked Netherlands reached the men's hockey final at the Paris Olympics on Tuesday with a much more comfortable 4-0 win over Spain than in the pool stage

Boxer Khelif is a victim of power struggle, says coach

The IOC says the IBA is a discredited organisation, mired in financial opaqueness and compromised by ties to the Russian leadership.